Saturday, October 04, 2014 4:15:22 PM
Of course it seems too good to be true -- that's why the stock is in the $3 range. The market, right or wrong, is basically calling bullshit.
It's laughable to suggest that it doesn't seem too good to be true. What's wrong about admitting it no matter how bullish one is? "Look, I know it seems too good to be true, but it really is." You'll catch a lot new blood into NNVC by admitting it sounds too good to be true. Denying it is an insult to people's intelligence.
Practice that line. Because if you run it by most educated people in the real world they will be quietly thinking to themselves "sounds too good to be true" because that's how rational people think when the only information about some rat hole claiming to cure everything from AIDS to Zits is found on message boards and pinksheet pump and dump sites and interviews by the CEO with 50 years of embarrassing commercial failure including 9 years of embarrassing deadline failure.
It's laughable to suggest that it doesn't seem too good to be true. What's wrong about admitting it no matter how bullish one is? "Look, I know it seems too good to be true, but it really is." You'll catch a lot new blood into NNVC by admitting it sounds too good to be true. Denying it is an insult to people's intelligence.
Practice that line. Because if you run it by most educated people in the real world they will be quietly thinking to themselves "sounds too good to be true" because that's how rational people think when the only information about some rat hole claiming to cure everything from AIDS to Zits is found on message boards and pinksheet pump and dump sites and interviews by the CEO with 50 years of embarrassing commercial failure including 9 years of embarrassing deadline failure.
The SwingTrade Portfolio is up 42.1% YTD through 8/8/2014, 83.5% in 2013, and 537.4% since inception.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=105141243
Recent NNVC News
- Deadly Measles Cases Accentuate the Need for a Treatment - NV-387 is Here to Help Patients and Control Spread, Says NanoViricides • ACCESS Newswire • 04/21/2026 12:30:00 PM
- Measles Rare Pediatric Disease Drug Designation Application Filed for NV-387, PRV Provides for Strong Business Case, Says NanoViricides • ACCESS Newswire • 04/07/2026 12:30:00 PM
- Phase II Clinical Trial of Monkeypox Treatment by NV-387 to Commence Soon, Announces NanoViricides • ACCESS Newswire • 04/01/2026 12:30:00 PM
- NanoViricides Presenting at NIBA's 152nd Investment Conference in Fort Lauderdale, FL March 12, 2026 - Announces Manufacture of Phase II Clinical Product NV-387 Oral Gummies is Complete • ACCESS Newswire • 03/11/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/17/2026 09:30:47 PM
- MPox Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides • ACCESS Newswire • 02/12/2026 01:30:00 PM
- Measles Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides • ACCESS Newswire • 02/10/2026 01:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 12/30/2025 09:30:18 PM
- Form DEL AM - Delaying amendment • Edgar (US Regulatory) • 12/16/2025 09:30:05 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 12/15/2025 09:26:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/26/2025 09:30:33 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:32:10 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/12/2025 07:54:28 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/12/2025 04:29:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/01/2025 09:07:54 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/29/2025 08:33:17 PM
